Ispire Technology Inc.
ISPRAbout the company
Ispire Technology Inc. researches, develops, designs, commercializes, sells, markets, and distributes e-cigarettes and cannabis vaping products worldwide under the Ispire and Aspire brands. The company was founded in 2010 and is headquartered in Los Angeles, California. Ispire Technology Inc. is a subsidiary of Pride Worldwide Investment Limited.
Investment snapshot
Positive
0
BUY / PASS
Neutral / negative
2 / 14
NEUTRAL / FAIL
Median fair value
—
No comparable estimates
Models with upside
0 / 17
Positive margin of safety
Key risk
No clean pass — all 16 investors flag at least one profitability criterion
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Graham Defensive Value | Buffett Quality Compounder | Lynch GARP | Greenblatt Magic Formula | Piotroski F-Score | Dreman Contrarian Value | Munger Quality Focus | Pabrai Dhandho Framework | Akre Three-Legged Stool | Marks Risk-Aware Value | Ackman Activist Value | Templeton Global Bargain Hunter | Sleep Scale Economies Shared | Asness Systematic Factors | Neff Low-P/E Total Return | Schloss Asset-Value Discipline | O'Shaughnessy Systematic Factor Composite |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | FAIL | FAIL | FAIL | Not ranked | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | NEUTRAL | FAIL | FAIL | NEUTRAL |
| Score | |||||||||||||||||
| Analysis | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Margin of Safety | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financial Basis | TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025 Latest source filing: 2026-11-09 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2025-09-15 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30 Latest source filing: 2026-11-09 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2025-09-15 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2025-09-15 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01 Latest source filing: 2026-11-09 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2025-09-15 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2025-09-15 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2025-09-15 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2025-09-15 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Market data at 2026-11-01 Latest source filing: 2026-11-09 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2025-09-15 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2025-09-15 Score computed: 2026-11-14 | TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025 Latest source filing: 2026-11-09 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2025-09-15 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-09 Score computed: 2026-11-14 | TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-11-09 Score computed: 2026-11-14 |
Where It Passes
Where It Falls Short
- Profitability0% pass✓ 1✗ 34▾
No clean pass — all 16 investors flag at least one profitability criterion
Positive EPS (10 years)0/6 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)✗Graham>= 33% growthNet Income Positive (10+ years)0/6 years positive✗BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)-2611.3%✗Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)-29.7% (latest)✗BuffettStable or rising over 10 yearsFree Cash Flow Proxy$-39.5M✗BuffettPositive and growingEarnings Variance (10-yr CoV)N/A (negative mean EPS)✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passROEN/A (negative equity)✗Lynch> 15%EBIT / Enterprise Value-51.7%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-51.7%, ROC=N/A (invested capital <= 0)✗GreenblattBoth EY > 10% and ROC > 25%Net Income / Total Assets-38.39%✗PiotroskiROA > 0ROA Change YoY-38.39% -> -38.39% (delta: +0.00%)✗PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=-7.21%, ROA=-38.39%✓PiotroskiCFO/Assets > ROAGross Margin Change YoY17.8% -> 17.8%✗PiotroskiImproved YoYPre-Tax Income / Revenue-38.0%✗Dreman>= 8%Net Income / Shareholders' Equity✗Dreman> 12%Margin of SafetyP/B=160.1x✗PabraiP/B < 1.5 or P/E < 15Return on Equity-4340.5% (3-yr avg)✗AkreROE > 20% (3-year avg)Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePositive Net Income Frequency0/5 years positive✗MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue-38.7%✗Ackman>= 15%Net Income / Shareholders Equity✗Ackman>= 15%5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Operating Margin Trend-9.1% (2023) -> -29.7% (2025)✗TempletonNon-negative operating-margin trend over 3 yearsRevenue growth vs. gross and operating margin trendgross margin 19.6% -> 17.8%, operating margin -9.1% -> -29.7%✗SleepRevenue rising; gross margin flat or falling; operating margin holdingNet income / market capitalization-37.27%; #4921/6340 (top 77.6%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionGross profit / total assets+21.97%; #1931/3702 (top 52.2%)✗AsnessTop 30% of eligible cross-sectionNet income / positive book equity✗AsnessTop 30% of eligible cross-sectionNegative 5-year standard deviation of ROA-0.1578; #3989/5884 (top 67.8%)✗AsnessTop 30% of eligible cross-section3-5 Year Diluted EPS CAGR✗Neff7%-20% annualizedPositive Diluted-EPS Years0/5 years positive✗Schloss>= 70% positive over 5-10 observed years (app rule) - Valuation0% pass✗ 28▾
All 13 investors flag ISPR's valuation
Price / 3-yr avg EPS✗Graham<= 15xPrice-to-Book Ratio160.1x✗Graham<= 1.5xP/E x P/B✗Graham<= 22.5Basic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)EBIT / Enterprise Value-51.7%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-51.7%, ROC=N/A (invested capital <= 0)✗GreenblattBoth EY > 10% and ROC > 25%Price / EPS✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)Price / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xPrice / Book Value per Share160.1x✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)Valuation ReasonablenessOE Yield=-40.8%✗MungerP/E < 25 or Owner Earnings Yield > 5%P/E or FCF YieldFCF Yield=-8.7%✗PabraiP/E < 15 or FCF Yield > 10%P/B or P/E vs. Historical AverageP/B=160.1x✗MarksP/E < 15 or P/B < 2.0Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePrice / FCF per ShareN/A (negative FCF)✗Ackman<= 25Price vs. Trailing Low130% of trailing low ($1.30)✗Templeton<= 120% of trailing low (certified split-adjusted live window)Net income / market capitalization-37.27%; #4921/6340 (top 77.6%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPositive book equity / market capitalization-0.3569; #5906/6449 (top 91.6%)✗AsnessTop 30% of eligible cross-sectionPrice / Diluted EPS✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E✗Neff> 0.7 (Neff's published traditional edge)Price / Tangible Book Value per Share160.08x✗SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change-95.5%✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Revenue / market capitalization+0.9547; #1814/5247 (top 34.6%)✗OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization-8.68%; #3181/4519 (top 70.4%)✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date-3.43%; #3037/6202 (top 49.0%)✗OshaughnessyTop 10% of eligible cross-section - Cash Flow0% pass✓ 1✗ 11▾
No clean pass — all 10 investors flag at least one cash flow criterion
Free Cash Flow Proxy$-39.5M✗BuffettPositive and growingFCF Positive and Growing$-8.5M✗LynchPositive and growingOperating Cash Flow$-7.4M✗PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=-7.21%, ROA=-38.39%✓PiotroskiCFO/Assets > ROAPrice / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xP/E or FCF YieldFCF Yield=-8.7%✗PabraiP/E < 15 or FCF Yield > 10%FCF Positive0/5 years FCF positive✗MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap-8.8%✗Ackman>= 4%Price / FCF per ShareN/A (negative FCF)✗Ackman<= 25Positive Operating Cash Flow frequency0/5 years positive✗SleepPositive OCF in >= 70% of available yearsOperating Cash Flow - Capital Expenditures$-8.5M✗Neff> $0 (app proxy for a strong fundamental case)(Operating cash flow - capex) / market capitalization-8.68%; #3181/4519 (top 70.4%)✗OshaughnessyTop 10% of eligible cross-section - Growth0% pass✓ 1✗ 12▾
No clean pass — all 8 investors flag at least one growth criterion
EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)✗Graham>= 33% growthBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passInventory Growth vs Revenue GrowthInv: -57.9% vs Rev: -21.3%✓LynchInventory growth < Revenue growthEPS Growth Direction$-0.04 (2021) -> $-0.69 (2025)✗DremanPositive over recent yearsEPS CAGR✗Dreman> 5% annualizedPositive Net Income Frequency0/5 years positive✗MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth0.0%✗Ackman>= 5%Positive EPS Growth Frequency0/4 years with positive EPS growth✗AckmanPositive EPS growth in >= 3 of last 5 years5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Revenue growth vs. gross and operating margin trendgross margin 19.6% -> 17.8%, operating margin -9.1% -> -29.7%✗SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR✗SleepCAGR > 7%3-5 Year Diluted EPS CAGR✗Neff7%-20% annualized - Efficiency0% pass✗ 11▾
All 8 investors flag ISPR's efficiency
Current Ratio1.01✗Graham>= 2.0ROIC (3-5 yr avg)✗Buffett> 10%ROIC - WACC✗BuffettPositive (WACC = 10%)EBIT / (NWC + Net Fixed Assets)N/A (invested capital <= 0)✗Greenblatt> 25%Current Ratio Change YoY1.01 -> 1.01✗PiotroskiIncreased YoYRevenue / Total Assets Change YoY1.25x -> 1.25x✗PiotroskiImproved YoYCurrent Assets / Current Liabilities1.01✗Dreman> 1.5Return on Invested Capital✗Munger> 15%ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROIC✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)✗SleepROIC > 12% in a majority of years - Verdicts0% pass✗ 14▾
Split decision: 14 FAIL · 2 NEUTRAL
Overall verdict✗GrahamFAIL (0/9)✗BuffettFAIL (0/9)✗LynchFAIL (1/7)•GreenblattNot ranked✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (0/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (0/5)✗AckmanFAIL (1/9)✗TempletonFAIL (1/8)✗SleepFAIL (2/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (1/6)✗SchlossFAIL (0/7)•OshaughnessyNEUTRAL (Not ranked) - Debt & Leverage8% pass✓ 1✗ 14▾
11 of 12 flag ISPR's debt & leverage — Graham, Buffett, Lynch +8 more
LT Debt vs Net Current Assets✗GrahamLT Debt <= Net Current AssetsDebt/Equity & Interest Coverage✗BuffettD/E < 0.5 AND Interest Coverage > 5xTotal Debt / Equity✗Lynch< 0.33Cash - Long-term Debt✗LynchPositive preferredLT Debt / Total Assets Change0.00% -> 0.00%✓PiotroskiDecreased YoYCurrent Assets / Current Liabilities1.01✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)Total Debt / Shareholders' Equity✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00xDebt Levels✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3Interest Coverage & Debt/EBITDAIC=-251.9x, D/EBITDA=N/A✗MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity✗Ackman<= 1.0Negative debt-to-equity (higher means less debt)✗AsnessTop 30% of eligible cross-section
Business & financials
Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Shareholder Return
Fiscal 2025
Issued 0.1% of shares last year, 1.4% issued over two.
- Buybacks
- —
- Dividends
- —
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.
| Metric | TTM · 2026-09-30 2025-10-01 – 2026-09-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, depreciation amortization, capex, buybacks, revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense. | Q1 FY 2027 2026-07-01 – 2026-09-30 Sources | FY 2025Sources
| FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
|
|---|---|---|---|---|---|---|---|
| Market Cap | $97.6Mcurrent | -- | $210.8Mest. | $273.2Mest. | $623.1Mest. | $491.5Mest. | -- |
| Revenue | $93.2M↓21% | $27.5M↓9% | $127.5M | $127.5M↓16% | $151.9M↑31% | $115.6M↑31% | $88.1M |
| Operating Income | -$36.0M↓2% | -$6.1M↓128% | -$37.8M | -$37.8M↓172% | -$13.9M↓211% | -$4.5M↓353% | -$988.7K |
| Net Income | -$36.4M↑1% | -$6.4M↓98% | -$39.2M | -$39.2M↓166% | -$14.8M↓146% | -$6.0M↓220% | -$1.9M |
| EPS (Diluted) | -- | $-0.11↓83% | $-0.69 | $-0.69↓156% | $-0.27↓125% | $-0.12↓200% | $-0.04 |
| Gross Margin | 12.5%↓27% | 16.2%↓5% | 17.8% | 17.8%↓9% | 19.6%↑9% | 18.0%↑19% | 15.1% |
| Operating Margin | -38.7%↓30% | -22.3%↓151% | -29.7% | -29.7%↓225% | -9.1%↓136% | -3.9%↓245% | -1.1% |
| ROE | 104.4%↓95% | — | -6489.3% | -6489.3%↓15041% | -42.9%↓125% | -19.1%↓20% | -15.9% |
| Total Debt | -- | -- | -- | -- | -- | -- | -- |
| Shareholders' Equity | -$34.8M↓1870% | -$34.8M↓1870% | $604.7K | $604.7K↓98% | $34.5M↑9% | $31.5M↑167% | $11.8M |
| Current Ratio | 1.01↓11% | 1.01↓11% | 1.01 | 1.01↓16% | 1.19↓21% | 1.52↑36% | 1.12 |
| Debt / Equity | — | — | — | — | — | — | — |
| Operating Cash Flow | -$1.0M↑92% | -$1.6M↓37% | -$7.4M | -$7.4M↑60% | -$18.3M↓116% | -$8.5M↓12% | -$7.6M |
| Free Cash Flow | -- | -$1.6M↓36% | -$8.5M | -$8.5M↑58% | -$20.3M↓114% | -$9.5M↓23% | -$7.7M |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Tobacco Products
ISPR vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Philip Morris International Inc.PM | $310.1B | $198.96 | $40.6B | $11.3B | -113.5% | -4.87 | 36.6% | 0.96 | 4/9 | 7/9 | 3/7 | 1/3 | F-Score 7 | 3/11 |
| British American Tobacco p.l.c.BTI | $132.9B | $61.89 | $34.5B | $10.5B | 16.9% | 0.76 | 39.0% | 0.87 | 1/9 | 0/9 | 3/7 | 0/3 | F-Score 6 | 4/11 |
| ALTRIA GROUP, INC.MO | $130.8B | $78.64 | $23.3B | $6.9B | -198.4% | -7.34 | 42.5% | 0.65 | 3/9 | 5/9 | 1/7 | 0/3 | F-Score 6 | 4/11 |
| RLX Technology Inc.RLX | $1.9B | $1.56 | $572.8M | $133.4M | 5.9% | 0.01 | 8.3% | 5.70 | 4/9 | 1/9 | 2/7 | 0/3 | F-Score 8 | 7/11 |
| Turning Point Brands, Inc.TPB | $1.1B | $55.55 | $463.1M | $58.2M | 15.6% | 0.80 | 20.6% | 5.56 | 3/9 | 5/9 | 2/7 | 1/3 | F-Score 6 | 4/11 |
| Healthier Choices Management Corp.HCMC | $26.4M | $0.00 | $34741.00 | $7.0M | 568.9% | — | -20243.9% | 0.84 | 0/9 | 0/9 | 0/7 | 0/3 | F-Score 4 | 0/11 |
| 22nd Century Group, Inc.XXII | $424,215 | $0.77 | $17.6M | $5.1M | -32.1% | 0.04 | -65.8% | 2.42 | 3/9 | 1/9 | 2/7 | 0/3 | F-Score 4 | 3/11 |